A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy
Open Access
- 1 January 2011
- journal article
- review article
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 3, 179-187
- https://doi.org/10.4137/jcnsd.s4888
Abstract
Eslicarbazepine acetate (ESL) is a novel antiepileptic drug indicated for the treatment of partial-onset seizures. Structurally, it belongs to the dibenzazepine family and is closely related to carbamazepine and oxcarbazepine. Its main mechanism of action is by blocking the voltage-gated sodium channel. ESL is a pro-drug that is rapidly metabolized almost exclusively into S-licarbazepine, the biologically active drug. It has a favorable pharmacokinetic and drug-drug interaction profile. However, it may induce the metabolism of oral contraceptives and should be used with caution in females of child-bearing age. In the pre-marketing placebo-controlled clinical trials ESL has proven effective as adjunctive therapy in adult patients with refractory of partial-onset seizures. Best results were observed on a single daily dose between 800 and 1200 mg. In general, ESL was well tolerated, with most common dose-related side effects including dizziness, somnolence, headache, nausea and vomiting. Hyponatremia has been observed (0.6%-1.3%), but the incidence appears to be lower than with the use of oxcarbazepine. There is very limited information on the use of ESL in children or as monotherapy.Keywords
This publication has 29 references indexed in Scilit:
- Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjectsCurrent Medical Research and Opinion, 2010
- Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsyEpilepsy Research, 2010
- Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjectsActa Neurologica Scandinavica, 2010
- Eslicarbazepine Acetate: A Well-Kept Secret?Epilepsy Currents, 2010
- Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjectsFundamental & Clinical Pharmacology, 2009
- Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2‐093), a new voltage‐gated sodium channel blockerBiopharmaceutics & Drug Disposition, 2007
- Eslicarbazepine Acetate: A Double‐blind, Add‐on, Placebo‐controlled Exploratory Trial in Adult Patients with Partial‐onset SeizuresEpilepsia, 2007
- The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- Neurotoxicity Induced by Antiepileptic Drugs in Cultured Hippocampal Neurons: A Comparative Study between Carbamazepine, Oxcarbazepine, and Two New Putative Antiepileptic Drugs, BIA 2‐024 and BIA 2‐093Epilepsia, 2004
- Interaction of the Novel Anticonvulsant, BIA 2‐093, with Voltage‐Gated Sodium Channels: Comparison with CarbamazepineEpilepsia, 2001